Depression and clinical progression in HIV-infected drug users with highly active antiretroviral therapy

INSERMU379/ORS-PACA, Marseilles, France.
Antiviral therapy (Impact Factor: 3.14). 02/2005; 10(1):53-61.
Source: PubMed

ABSTRACT To disentangle the impact of adherence from that of injecting drug status and depressive syndrome on HIV clinical progression in a cohort of highly active antiretroviral therapy (HAART)-treated HIV patients infected through drug use.
MANIF 2000 is a French cohort of HIV-infected drug users with scheduled medical visits every 6 months. Only patients enrolled in the MANIF 2000 cohort who had a CD4 cell count >200 cells/microl at HAART initiation were selected. The follow-up period included all post-HAART initiation visits.
HIV clinical progression was defined as either AIDS-related death or reaching a CD4 level <200 cells/microl. Adherence was assessed using a self-administered questionnaire and a structured face-to-face interview. Depressive symptoms were evaluated by a Center for Epidemiologic Studies Depression Scale (CES-D) score at each visit. Cox proportional hazards model was used to calculate crude and adjusted relative hazards and 95% confidence intervals and thus identify independent predictors of clinical progression.
Of the 305 HAART-treated patients in the cohort, 243 had CD4 cell count >200 cells/microl at HAART initiation. At the first visit after HAART initiation, median CD4 cell count was 466 cells/microl and 45% had undetectable viral load. Injecting drug users accounted for 17% of the study group. Over the follow-up period, 32 patients experienced HIV clinical progression. Probable depression was encountered in 46% of patients and non-adherence in 31% of the sample. After adjustment on baseline CD4 cell count, predictors of clinical progression were: having a higher level of cumulative non-adherence over the follow-up period [HR (95% CI)=1.2 (1.1-1.3) per 10% increase] and having a high score of depressive symptoms following HAART initiation [HR (95% CI)=5.3 (2.21-3.0)].
Although depressive syndrome is known to influence non-adherence behaviours that are amongst the major reasons for clinical progression, it is also a predictor of clinical progression in HIV-infected intravenous drug users on HAART, independently of non-adherence behaviours. HIV care providers should be more sensitive to depressive symptoms in order to detect them early and supply HIV patients with specific care. Further research is needed to determine whether treating depressive symptoms may improve adherence and thus delay disease progression and mortality.

Download full-text


Available from: Anne-Déborah Bouhnik, Aug 24, 2015
  • Source
    • "Rates of suicide are significantly increased among depressed patients. The association between hopelessness, depression and suicide has been well documented [10]. Hopelessness, being a feeling of despair and extremely pessimism about the future, forms part of PHQ-9 questionnaire of depression. "
    Open Journal of Medical Psychology 01/2014; 3(01):60-69. DOI:10.4236/ojmp.2014.31008
  • Source
    • "With a longitudinal design, it has been shown that an increase in spirituality/religiousness after HIV diagnosis can predict a slower disease progression (Ironson, Stuetzle, & Fletcher, 2006). Moreover, several psychosocial factors related to HIV progression such as depression (Bouhnik et al., 2005), hopelessness, optimism, coping (avoidant, proactive) and social support have been identified after adjustment on immuno-virological characteristics and adherence. Adherence has been shown to be influenced by disclosure (Peretti-Watel, Spire, Pierret, Lert, & Obadia, 2006). "
  • Source
    • "As Thailand continues the widespread use of ART with PLH, similar challenges are anticipated (Ammassari et al., 2004). In addition, a growing body of evidence suggests that psychosocial factors, including depression, HIV-related stigma, family relationships, and HIV status disclosure, play an important role in ART adherence (Tucker et al., 2003; Ammassari et al., 2004; Bouhnik et al., 2005; Hartzell et al., 2007; Ncama et al., 2008). As a result of their physical debilitation and the psychological impact of coping with HIV infection, PLH remain highly vulnerable to social isolation (Singh et al., 1999); social support might play a significant role in ART adherence (Ncama et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The importance of antiretroviral therapy adherence for patients living with HIV/AIDS has been well documented. Despite this critical need, many do not follow prescribed regimens. To examine the barriers that lead to non-adherence, we used cross-sectional survey data from a randomized controlled intervention trial in northern and north-eastern Thailand. Of the 507 patients that were enrolled in the trial, we analyzed 386 patients on antiretroviral therapy in order to examine the barriers to adherence. In addition to demographic characteristics, depressive symptoms, physical health, access to care, social support, and internalized shame, HIV disclosure and family communication were examined. The correlation analysis revealed that adherence is significantly associated with internalized shame, access to care, depressive symptoms, and family communication. Based on the multiple logistic regression analysis, depressive symptoms, access to care, HIV disclosure, and family communication were significant predictors of adherence. Having depressive symptoms remains a significant barrier to adherence, while access to care, HIV disclosure, and family communication play important positive roles. Our findings underscore the critical importance of addressing these various challenges that can influence adherence to antiretroviral therapy.
    Nursing and Health Sciences 03/2010; 12(2):212 - 220. DOI:10.1111/j.1442-2018.2010.00521.x · 0.85 Impact Factor
Show more